Letters Generic drug pricing

The scandal of generic drug pricing: drug regulation policies need review

BMJ 2017; 356 doi: https://doi.org/10.1136/bmj.j947 (Published 23 February 2017) Cite this as: BMJ 2017;356:j947
  1. Karim Meeran, professor of endocrinology1,
  2. Sirazum M Choudhury, specialist registrar in metabolic medicine2,
  3. John Wass, chair of the endocrinology clinical reference group and professor of endocrinology3
  1. 1Department of Endocrinology, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London W6 8RF, UK
  2. 2Department of Clinical Biochemistry, Imperial College Healthcare NHS Trust, Charing Cross Hospital
  3. 3Churchill Hospital, Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford, UK
  1. k.meeran{at}imperial.ac.uk

We welcome the news that the Competitions and Market Authority is now taking drug companies such as GlaxoSmithKline, Pfizer, and Flynn Pharma to task for overcharging the NHS for generic drugs.1 In December, the authority announced that it was investigating Actavis for inflating the price of hydrocortisone, a WHO essential medicine used to treat adrenal insufficiency.2

The price of hydrocortisone has risen by …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe